DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm

The owner of DIAGOMICS has sold the company to ZytoMax GmbH.

Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.

Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.

Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.

Servicio

M&A sell-side

Partes

“DIAGOMICS has reached a strategic turning point given its rapid and exponential growth. To strengthen our market position and continue to offer innovative and quality products, DIAGOMICS is joining the ZytoMax group. Our shared values, such as scientific expertise and customer proximity, contributed to this choice.”

Gwénola Tanneau

Founder and CEO, DIAGOMICS

Contáctese con el equipo de la transacción

Xavier Auvergnat

Socio

Toulouse, Francia
Oaklins France

Ver perfil Contáctenos

Théo Cavalière

Analista

Toulouse, Francia
Oaklins France

Ver perfil Contáctenos

Transacciones relacionadas

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

Salud

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

Aprenda más

Groupe JVS has completed an LBO with Capza and Bpifrance

Private Equity | TMT

Groupe JVS has completed an LBO with Capza and Bpifrance

The shareholders of Groupe JVS have completed an LBO with Capza and BpiFrance. Parquest sold their shares after partnering with the organization for three years. Groupe JVS’s management team will increase its ownership and remain as the majority shareholder of the group, alongside CAPZA and Bpifrance.

Aprenda más

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Salud

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.

Aprenda más